

Shi-Ming Tu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7188418/publications.pdf>

Version: 2024-02-01

88
papers

2,326
citations

279798

23
h-index

243625

44
g-index

89
all docs

89
docs citations

89
times ranked

2492
citing authors

#	ARTICLE	IF	CITATIONS
1	Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality. <i>Seminars in Diagnostic Pathology</i> , 2023, 40, 63-68.	1.5	2
2	Somatic-type Malignancies in Testicular Germ Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2022, 46, 11-17.	3.7	12
3	Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?. <i>Cancers</i> , 2022, 14, 655.	3.7	8
4	Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. <i>Cancers</i> , 2022, 14, 1127.	3.7	8
5	Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies. <i>Cancers</i> , 2022, 14, 1338.	3.7	2
6	Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care. <i>Cancers</i> , 2022, 14, 1548.	3.7	8
7	Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. <i>Cancers</i> , 2022, 14, 3345.	3.7	4
8	Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. <i>European Urology Oncology</i> , 2021, 4, 651-658.	5.4	25
9	A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 22-31.e5.	1.9	8
10	Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. <i>European Urology</i> , 2021, 79, 298-306.	1.9	24
11	Testicular germ cell tumors type 2 have high RNA expression of LDHB, the gene for lactate dehydrogenase subunit B. <i>Asian Journal of Andrology</i> , 2021, 23, 357.	1.6	5
12	Curing Cancer: Lessons from a Prototype. <i>Cancers</i> , 2021, 13, 660.	3.7	4
13	The Cancer Genome: Paradigm or Paradox?. <i>Cancers</i> , 2021, 13, 674.	3.7	1
14	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 558-e1098.	3.7	18
15	Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. <i>Investigational New Drugs</i> , 2021, 39, 1405-1410.	2.6	35
16	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021, 5, 21.	5.4	12
17	Optimizing the diagnosis and management of ductal prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 337-358.	3.8	21
18	Very late recurrence in germ cell tumor of the testis: Lessons and implications.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5030-5030.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Stem Cell Theory of Cancer: Implications of a Viral Etiology in Certain Malignancies. <i>Cancers</i> , 2021, 13, 2738.	3.7	5
20	Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. <i>Cancers</i> , 2021, 13, 4006.	3.7	18
21	Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. <i>European Journal of Cancer</i> , 2021, 157, 259-267.	2.8	4
22	Diagnostic performance of F-fluciclovine PET/CT in prostate cancer patients with rising PSA level \geq 0.5 ng/ml after multiple treatment failures. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 87-98.	1.0	2
23	Application of a Successful Germ Cell Tumor Paradigm to the Challenges of Common Adult Solid Cancers. <i>Journal of Cell Science & Therapy</i> , 2021, 12, .	0.3	2
24	Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. <i>Cancer</i> , 2020, 126, 4878-4885.	4.1	5
25	Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. <i>Cancers</i> , 2020, 12, 3755.	3.7	23
26	Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. <i>Clinical Nuclear Medicine</i> , 2020, 45, 349-355.	1.3	7
27	Patterns of metastases of prostatic ductal adenocarcinoma. <i>Cancer</i> , 2020, 126, 3667-3673.	4.1	14
28	Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment. <i>Translational Andrology and Urology</i> , 2020, 9, S56-S65.	1.4	7
29	A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 990-999.	7.0	11
30	A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 127, 67-75.	2.8	6
31	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
32	Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture <i>In Vitro</i> and Reduces Bone Osteolysis <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1266-1278.	4.1	9
33	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 1154-1154.	0.4	0
34	Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1&2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1432-1443.	10.7	115
35	Primary Malignant Thyroid Teratoma: An Institutional Experience. <i>Thyroid</i> , 2019, 29, 229-236.	4.5	11
36	Rapidly enlarging abdominal mass in a patient with recurrent germ cell tumor. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2285-2286.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Managing seminomatous and nonseminomatous germ cell tumors. <i>Current Opinion in Oncology</i> , 2018, 30, 181-188.	2.4	7
38	Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 325-327.	1.9	2
39	Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e429-e435.	1.9	10
40	Recent developments in the management of germ cell tumors. <i>Current Opinion in Oncology</i> , 2017, 29, 172-178.	2.4	3
41	Postacute Care in Cancer Rehabilitation. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2017, 28, 19-34.	1.3	3
42	Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e73-e77.	1.9	2
43	Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 583-589.	2.3	6
44	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. <i>Cancer</i> , 2016, 122, 1836-1843.	4.1	39
45	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. , 2016, 4, 36.		90
46	Personalised cancer care: promises and challenges of targeted therapy. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 98-105.	2.0	13
47	Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. <i>Oncotarget</i> , 2016, 7, 86280-86289.	1.8	25
48	Association of Body Composition with Outcome of Docetaxel Chemotherapy in Metastatic Prostate Cancer: A Retrospective Review. <i>PLoS ONE</i> , 2015, 10, e0122047.	2.5	30
49	Maintenance Therapy Containing Metformin and/or Zylflamend for Advanced Prostate Cancer: A Case Series. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-5.	0.3	10
50	Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. <i>Cancer</i> , 2015, 121, 69-76.	4.1	13
51	A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5075-TPS5075.	1.6	2
52	The scientific method: pillar and pitfall of cancer research. <i>Cancer Medicine</i> , 2014, 3, 1035-1037.	2.8	11
53	Positive FDG-PET/CT Scans of a Residual Seminoma After Chemotherapy and Radiotherapy: Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e147-e150.	1.9	6
54	Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4517-4517.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Variant prostate carcinoma and elevated serum CA-125. Canadian Journal of Urology, 2014, 21, 7442-8.	0.0	4
56	Stem Cell Origin of Testicular Seminoma. Clinical Genitourinary Cancer, 2013, 11, 489-494.	1.9	9
57	Cancer: a stem-cell disease?. Cancer Cell International, 2013, 13, 40.	4.1	13
58	Recurrent seminomas: Clinical features and biologic implications. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 494-501.	1.6	6
59	Prostate Cancer Stem Cells. Clinical Genitourinary Cancer, 2012, 10, 69-76.	1.9	33
60	Radiopharmaceuticals: Present and Future. The Journal of Supportive Oncology, 2011, 9, 206-207.	2.3	1
61	Prolonged Remission of Fulminant Castrate-Resistant Prostate Cancer: A Case Report. Clinical Genitourinary Cancer, 2011, 9, 133-136.	1.9	0
62	Pilot Trial of Bone-Targeted Therapy Combining Zoledronate With Fluvastatin or Atorvastatin for Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2011, 9, 81-88.	1.9	18
63	Introduction. Cancer Treatment and Research, 2010, 154, 1-5.	0.5	23
64	Cancer Stem Cells. Cancer Treatment and Research, 2010, , 67-81.	0.5	2
65	Cancer Niche. Cancer Treatment and Research, 2010, , 83-91.	0.5	0
66	Curing Cancer. Cancer Treatment and Research, 2010, , 215-225.	0.5	0
67	Drug Resistance. Cancer Treatment and Research, 2010, , 161-175.	0.5	0
68	Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clinical Advances in Hematology and Oncology, 2010, 8, 341-51.	0.3	11
69	Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 3319-3324.	1.6	46
70	Ductal adenocarcinoma of the prostate. Cancer, 2009, 115, 2872-2880.	4.1	56
71	Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer. Clinical Cancer Research, 2008, 14, 3729-3736.	7.0	23
72	Current Trials Using Bone-Targeting Agents in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 35-39.	2.0	25

#	ARTICLE	IF	CITATIONS
73	Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases. <i>Clinical Cancer Research</i> , 2007, 13, 5816-5824.	7.0	84
74	The central role of osteoblasts in the metastasis of prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2007, 25, 601-609.	5.9	31
75	Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon- γ for metastatic renal cell carcinoma. <i>Cancer</i> , 2006, 107, 497-505.	4.1	14
76	Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 7904-7910.	1.6	63
77	Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. <i>Journal of Pathology</i> , 2004, 203, 688-695.	4.5	36
78	Clinical Aspects of Bone Metastases in Prostate Cancer. <i>Cancer Treatment and Research</i> , 2004, 118, 23-46.	0.5	18
79	Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. <i>Cancer</i> , 2003, 97, 561-567.	4.1	26
80	A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. <i>Cancer</i> , 2003, 97, 2988-2994.	4.1	39
81	Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, \pm -interferon, cisplatin (FAP). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 342-348.	1.6	2
82	Stem-cell origin of metastasis and heterogeneity in solid tumours. <i>Lancet Oncology</i> , The, 2002, 3, 508-513.	10.7	149
83	Prostate carcinoma with testicular or penile metastases. <i>Cancer</i> , 2002, 94, 2610-2617.	4.1	115
84	ADULT PROSTATE SARCOMA: THE M. D. ANDERSON CANCER CENTER EXPERIENCE. <i>Journal of Urology</i> , 2001, 166, 521-525.	0.4	153
85	Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. <i>Lancet</i> , The, 2001, 357, 336-341.	13.7	384
86	A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2000, 89, 615-618.	4.1	44
87	Phase II trial of 5-fluorouracil, interferon- γ and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. <i>Cancer</i> , 1997, 80, 2128-2132.	4.1	62
88	Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1996, 2, 191-197.	1.6	30